StockNews.com Upgrades Ascendis Pharma A/S (NASDAQ:ASND) to Hold

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday.

Several other research analysts have also issued reports on the company. Evercore ISI upped their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. JPMorgan Chase & Co. reduced their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. Wedbush reaffirmed an “outperform” rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, The Goldman Sachs Group boosted their price target on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Trading Up 2.0 %

ASND opened at $124.44 on Wednesday. The firm has a market cap of $7.55 billion, a price-to-earnings ratio of -15.40 and a beta of 0.66. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00. The stock has a fifty day moving average price of $132.59 and a 200-day moving average price of $132.38.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. On average, equities research analysts forecast that Ascendis Pharma A/S will post -7.3 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds have recently modified their holdings of ASND. Bessemer Group Inc. boosted its stake in shares of Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after buying an additional 332 shares during the last quarter. Capital International Investors raised its holdings in Ascendis Pharma A/S by 0.5% in the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after purchasing an additional 10,044 shares during the period. Avoro Capital Advisors LLC raised its holdings in Ascendis Pharma A/S by 5.6% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,966,666 shares of the biotechnology company’s stock worth $599,641,000 after purchasing an additional 211,111 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after purchasing an additional 336,976 shares during the period. Finally, Farallon Capital Management LLC acquired a new position in Ascendis Pharma A/S in the 1st quarter worth about $16,478,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.